Gismo Therapeutics Inc.

Gismo Therapeutics Inc. is a biotechnology company focused on developing first-in-class, disease-modifying oral therapeutics for neurodegenerative conditions, specifically Alzheimer’s and Parkinson’s disease. The company was founded by Dr. Paul Gregor on the basis of its proprietary Glycosaminoglycan-Interacting Small Molecule (GISMO) technology. This platform targets fundamental biochemical processes involving heparan sulfate glycosaminoglycans (HS-GAGs), which are implicated in the internalization and aggregation of amyloid-beta and tau proteins, as well as alpha-synuclein, which drive the pathogenesis of amyloid diseases. By inhibiting these interactions, the company aims to reduce the propagation of aggregated proteins in the central nervous system.

The company serves as a developer of novel chemical entities intended to halt disease progression rather than simply manage symptoms. Their lead programs, such as GTC-3295 for Alzheimer’s disease, have demonstrated the ability to significantly decrease amyloid burden and hyperphosphorylated tau levels in preclinical transgenic mouse models. The company’s research has been supported by multiple grants from organizations including the National Institutes of Health (NIH) and the Michael J. Fox Foundation. Gismo Therapeutics actively pursues collaborative partnerships with academic institutions, such as the University of Kentucky and the Van Andel Research Institute, to advance its pipeline toward clinical trials and future therapeutic deployment.